Associate Professor, Pediatrics, University of Tennessee Health Science Center College of Medicine
Pediatric Infectious Disease
Dr. Karen S. Slobod, MD
|
|
Give Review
Karen S. Slobod is an expert in the field of Pediatric Infectious Disease. Karen S. Slobod, MD is also a published doctor. He has 60 paper published. The most recent paper is: Primary central nervous system lymphoma in a child with acute B-cell lymphoblastic leukaemia: consecutive Epstein-Barr virus-related malignancies.
Publications
- Safety and immunogenicity of an intranasal sendai virus-based human parainfluenza virus type 1 vaccine in 3- to 6-year-old children.
- Sendai virus recombinant vaccine expressing a secreted, unconstrained respiratory syncytial virus fusion protein protects against RSV in cotton rats.
- Prevention of group B streptococcal disease in the first 3 months of life: Would routine maternal immunization during pregnancy be cost-effective?
- Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model.
- Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.
- Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.
- Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.
- Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine.
- Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infecti...
- First phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: immune activity induced in all study participants.
- HIV-1 vaccine development: tackling virus diversity with a multi-envelope cocktail.
- Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection agains...
- A recombinant Sendai virus is controlled by CD4+ effector T cells responding to a secreted human immunodeficiency virus type 1 envelope glycoprotein.
- HIV-1 envelope T cell epitope "hotspots " among mice and humans and among CD4+ and CD8+ T cell subpopulations.
- Individual HIV type 1 envelope-specific T cell responses and epitopes do not segregate by virus subtype.
- Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV.
- HIV vaccines: brief review and discussion of future directions.
- The HIV pandemic: a forgotten crisis?
- Application of the polyvalent approach to HIV-1 vaccine development.
- CD8+ T-cells: are they sufficient to prevent, contain or eradicate HIV-1 infection?
- Clade, Country and Region-specific HIV-1 Vaccines: Are they necessary?
- HIV vaccine rationale, design and testing.
- Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy.
- T cell epitope "hotspots" on the HIV Type 1 gp120 envelope protein overlap with tryptic fragments displayed by mass spectrometry.
- Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus.
- Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults.
- Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV.
- Minor components of a multi-envelope HIV vaccine are recognized by type-specific T-helper cells.
- Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1.
- Clustering of Th cell epitopes on exposed regions of HIV envelope despite defects in antibody activity.
- Inhibition of ex vivo-expanded cytotoxic T-lymphocyte function by high-dose cyclosporine.
- Limited breadth of a T-helper cell response to a human immunodeficiency virus envelope protein.
- Do the immunosuppressive drugs used as treatment for graft-versus-host disease directly inhibit lymphoid tumor cell growth?
- A five-residue HIV envelope helper T cell determinant: does this peptide-MHC interaction leave the binding groove half empty?
- Effect of extended immunosuppressive drug treatment on B cell vs T cell reconstitution in pediatric bone marrow transplant recipients.
- Structural features of HIV envelope defined by antibody escape mutant analysis.
- Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing.
- T cell immunotherapeutic populations control viral infections in bone marrow transplant recipients.
- Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer.
- Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system.
- Molecular evidence of ocular Epstein-Barr virus infection.
- Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees.
- Primary central nervous system lymphoma in a child with acute B-cell lymphoblastic leukaemia: consecutive Epstein-Barr virus-related malignancies.
- Profound abnormality of the B/T lymphocyte ratio during chemotherapy for pediatric acute lymphoblastic leukemia.
- Expression of the human immunodeficiency virus type 1 primer binding sequence inhibits HIV-1 replication.
- Pulmonary complications in children with hematologic malignancies: accuracy of diagnosis with chest radiography and CT.
- Drift from the GPGRAF HIV-1 envelope V3 crown sequence in a North American inner city.
- Mobilization of CD34+ progenitor cells by granulocyte colony-stimulating factor in human immunodeficiency virus type 1-infected adults.
- Fluctuating diversity in the HTLV-IIIB virus stock: implications for neutralization and challenge experiments.
- Does the key to a successful HIV type 1 vaccine lie among the envelope sequences of infected individuals?
- Does envelope V3 peptide comprise the principal neutralizing determinant for HIV?
- Activity of transplanted CD8+ versus CD4+ cytotoxic T cells against Epstein-Barr virus-immortalized B cell tumors in SCID mice.
- Cavitary lung lesions in an immunosuppressed child.
- HIV type 1 envelope sequence diversity in inner city community.
- Trimethoprim-sulfamethoxazole-resistant pneumococcal disease in a pediatric acquired immunodeficiency syndrome patient receiving trimethoprim-sulfamethoxazole prophyla...
- Viral cross-reactivity and antigenic determinants recognized by human parainfluenza virus type 1-specific cytotoxic T-cells.
- Peripheral T cell receptor repertoire among CD4+ and CD8+ subsets during acute infectious mononucleosis.
- Parainfluenza type 1 virus-infected cells are killed by both CD8+ and CD4+ cytotoxic T cell precursors.
- T-cell receptor heterogeneity among Epstein-Barr virus-stimulated T-cell populations.
Schools
McGill University Faculty of Medicine
Montreal Chldn39s Hospital
St Jude
Doctors Specialties
- Pediatric Infectious Disease Medicine
- Pediatric Infectious Disease
Accepted Insurances
- MultiPlan PPO
- PHCS Network PPO
- Qualchoice PPO
Education
-
McGill University Faculty of Medicine
Hospital
-
University of Tennessee Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Monique A. Foster, MD |
|
Dr. Steven C. Buckingham, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Boyce K. English, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Fred F. Barrett, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patricia M. Flynn, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. John Devincenzo, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Akinobu Kamei, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gabriela M. Maron, MD |